Literature DB >> 19426804

Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization.

Silvia Vendetti1, Antonella Riccomi, Donatella R M Negri, Filippo Veglia, Ester Sciaraffia, Maria Teresa De Magistris.   

Abstract

The power of cholera toxin (CT) as an effective mucosal adjuvant is well established. Because of the high toxicity of CT, its clinical use is unlikely. Therefore, the need to identify effective and non toxic mucosal adjuvants for human use is important. For this purpose, CT is largely used as a reference molecule for testing the efficacy of new candidate adjuvants in animal models. Here, we evaluated the kinetics and the localization of antigen-specific humoral and cellular immune responses elicited by intranasal immunization with tetanus toxoid antigen in the presence of CT. We show that an antigen-specific cellular immune response localized in the mediastinal lymph nodes can be observed already 1 week after the first immunization. The induction of an appreciable titer of an antibody-specific immune response was assessed after two immunizations. Therefore, we suggest that the efficacy of new candidate mucosal adjuvants can be tested by evaluating the cellular immune response in the mediastinal lymph nodes at early stages of immunization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426804     DOI: 10.1016/j.ymeth.2009.04.018

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  2 in total

1.  Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice.

Authors:  Annalisa Ciabattini; Elena Pettini; Fabio Fiorino; Gennaro Prota; Gianni Pozzi; Donata Medaglini
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

2.  The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages.

Authors:  Ivana Škrnjug; Christine Rueckert; Rimma Libanova; Stefan Lienenklaus; Siegfried Weiss; Carlos A Guzmán
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.